BPTH News and Press, Bio-Path Holdings Inc. From 03/27/25

HG Holdings Inc (STLY) is expected to report for quarter end 2024-12-31 Savara Inc. (SVRA) is expected to report $-0.11 for Q4 2024 Reborn Coffee Inc. (REBN) is expected to report for quarter end 2024-12-31 VSee Health Inc. (VSEE) is expected to report for Q4 2024 IceCure Medical ...

Papaya Growth Opportunity Corp. I (PPYA) is expected to report for quarter end 2024-12-31 KinderCare Learning Companies Inc. (KLC) is expected to report $0.04 for Q4 2024 Recordati SpA (RCDTF) is expected to report for quarter end 2024-12-31 InflaRx N.V. (IFRX) is expected to report $...

HOUSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today reported results f...

Team Inc. (TISI) is expected to report for quarter end 2024-12-31 Chesswood Group Limited (CHWWQ) is expected to report for Q4 2024 J. W. Mays Inc. (MAYS) is expected to report for Q2 2025 Allakos Inc. (ALLK) is expected to report $-0.17 for Q4 2024 Aurora Mobile Limited (JG) is e...

Air France-KLM ADR (AFLYY) is expected to report $0.02 for Q4 2024 Viracta Therapeutics Inc. (VIRX) is expected to report for Q4 2024 BJ's Wholesale Club Holdings Inc. (BJ) is expected to report $0.89 for Q4 2025 Deutsche Lufthansa AG ADR - Level I (DLAKY) is expected to report $0.22 ...

First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease Reports Continued Patient Progress from Phase 2 Triple Combination Study of Prexigebersen in Acute Myeloid Leukemia (AML) HOUSTON...

Study Progresses to Fourth Higher 90 mg/m 2 Dose Cohort Compelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast Count After One Treatment Cycle HOUSTON, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biote...

Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbi...